Altimmune, Inc. (NASDAQ: ALT) Director Increases Stake Amid Promising Drug Developments

Core Insights - Altimmune, Inc. has received Breakthrough Therapy Designation from the FDA for its drug pemvidutide, indicating significant potential for improvement over existing therapies for serious liver diseases [2][6] - The company reported promising 48-week Phase IIb data for pemvidutide, showing durable improvements in non-invasive fibrosis markers and a weight loss of 7.5% at a 1.8 mg dose, supporting progression to Phase III trials [3][6] - Altimmune is optimistic about regulatory alignment for a Phase III trial, which will focus on biopsy-based endpoints and test a 2.4 mg dose [4][6] Stock Performance - The stock price of Altimmune is currently at $4.09, reflecting a significant increase of 16.52% with a change of $0.58, indicating investor confidence [4] - Over the past year, the stock has fluctuated between a low of $2.90 and a high of $7.83, with a current market capitalization of approximately $361 million and a trading volume of 26.77 million shares [5]